Jaime Davidson, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical School
Dallas, Texas
Indiana University School of Medicine requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. Conflict resolution must occur prior to the CME/CE activity. Indiana University School of Medicine also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
This CME activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Indiana University School of Medicine requires the speaker to disclose that a product is not labeled for the use under discussion. The provider’s documentation of common practices that make the disclosure requirement known to faculty demonstrates compliance with ACCME guidelines.
The following disclosure information has been provided.
Jaime Davidson, MD
Consulting Agreements/Advisory Board: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Aspire Bariatrics, Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lifescan, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; Novo Nordisk A/S; Roche Diagnostics; sanofi-aventis U.S. LLC.
Speakers’ Bureau: Janssen Pharmaceuticals, Inc.; Novo Nordisk A/S; Takeda Pharmaceuticals North America, Inc.
All Academy for Continued Healthcare Learning and Indiana University School of Medicine staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
